{"product_id":"abcam-ab258534","title":"Abcam, ab258534, Human NLRC5 knockout A549 cell lysate","description":"\u003cp\u003eSize: 1Kit\u003cbr\u003e\nNLRC5 KO cell lysate available now. KO validated by. Free of charge wild type control included. Knockout achieved by using CRISPR\/Cas9, 13 bp deletion in exon5 and 1 bp insertion in exon5 and 8 bp deletion in exon5.\u003cbr\u003e\nKey facts\u003cbr\u003e\nCell type:A549,\u003cbr\u003e\nSpecies or organism:Human,\u003cbr\u003e\nTissue:Lung,\u003cbr\u003e\nKnockout validation:Sanger Sequencing,\u003cbr\u003e\nMutation description:Knockout achieved by using CRISPR\/Cas9, 13 bp deletion in exon5 and 1 bp insertion in exon5 and 8 bp deletion in exon5.,\u003cbr\u003e\nDisease:Carcinoma\u003c\/p\u003e\n\n\u003cp\u003eProduct details:\u003cbr\u003e\nKnockout cell lysate achieved by CRISPR\/Cas9.\u003cbr\u003e\nREACH authorisation\u003cbr\u003e\nAbcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.\u003cbr\u003e\nIt is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.\u003cbr\u003e\nLysate preparation:\u003cbr\u003e\nOur lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).\u003cbr\u003e\nThis means that the protein of interest is denatured.\u003cbr\u003e\nIf you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.\u003cbr\u003e\nUser storage instructions:\u003cbr\u003e\nLyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.\u003cbr\u003e\nThis product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our\u003cbr\u003e\nlimited use license\u003cbr\u003e\npatent pages\u003c\/p\u003e\n\n\u003cp\u003eProperties and Storage Information:\u003cbr\u003e\nGene name-NLRC5, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C\u003c\/p\u003e\n\n\u003cp\u003eSupplementary Information:\u003cbr\u003e\nThis supplementary information is collated from multiple sources and compiled automatically.\u003cbr\u003e\nNLRC5 also known as NOD-like receptor family CARD domain-containing 5 is an important protein in the immune response. It has a molecular mass of approximately 186 kDa. This protein locates primarily in the cytoplasm of cells with high expression levels in immune tissues such as the spleen and lymph nodes. Mechanically NLRC5 acts as a transcriptional regulator controlling the expression of major histocompatibility complex (MHC) class I genes. This function plays a critical role in the immune system by facilitating the presentation of endogenous antigens.\u003cbr\u003e\nBiological function summary\u003cbr\u003e\nNLRC5 engages in enhancing immune surveillance and antiviral responses by regulating MHC class I transcription. It acts as part of the larger NLR family of proteins which are known to participate in the immune system's response to pathogens. In addition to its role in the immune response NLRC5 can interact with components of the inflammasome complex although its presence in the inflammasome remains controversial. These mechanisms are essential in initializing and sustaining an immune response against infections.\u003cbr\u003e\nPathways\u003cbr\u003e\nNLRC5 involves itself in the interferon signaling pathway and antigen processing and presentation pathways. In the context of interferon signaling NLRC5 influences the activation of genes that drive antiviral states by interacting with proteins such as IRF1 and STAT1. This regulatory role positions NLRC5 as a bridge between innate and adaptive immune responses ensuring proper signaling and presentation of antigens to T cells for effective immune resolution.\u003cbr\u003e\nNLRC5 exhibits alterations in conditions such as some auto-inflammatory disorders and cancer. Deregulation of NLRC5 can contribute to diseases like systemic lupus erythematosus where its altered expression affects immune function and tolerance. In certain cancers such as hepatocellular carcinoma NLRC5 interacts with oncogenic pathways influencing tumor growth and immune evasion. Researchers explore connections between NLRC5 and proteins like MHC class I molecules to understand their roles in disease mechanisms and therapeutic potentials.\u003c\/p\u003e","brand":"Abcam","offers":[{"title":"Default Title","offer_id":46845189652649,"sku":"ab258534","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/abcam-ab258534","provider":"Iright","version":"1.0","type":"link"}